May 12, 2020 5:48pm
Sometimes it’s up, and sometimes it’s down as indexes erase gains like gravity causes “things” to fall
Pre-open indications follow-up: 3 HITs < ReNeuron (RENE.L -$1.50), Athersys (ATHX -$0.21), Fate Therapeutics (FATE -$1.74), and 2 MISS < Sangamo Therapeutics (SGMO +$0.73), CRISPR Therapeutics (CRSP -$1.74)>
An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector. Check the BOTTOM LINE <read more>
The Dow closed DOWN -457.21 points (-1.89%), the S&P closed DOWN -60.20 points (-2.05 %) while the NASDAQ closed DOWN -189.79 points (-2.06%)
Henry’omics:
Markets have been torn between optimism and re-opening as …
Indexes struggled in trading to end the day in the red Tuesday as investors “estimated” attempts or possible results to reopen the economy.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and other health officials testified before the Senate Health Committee to discuss reopening the economy. Fauci “noted a vaccine will be essential in stopping the coronavirus spread, but warned it will be a while before a usable one is available.” <CNBC>
- While former FDA Commissioner Scott Gottlieb said Tuesday, he expects coronavirus cases to rise as more states reopen.
Volume INCREASED with 8 out of the 11-upside having higher than the 3-month average volume and remained LOW with 9 out of the 21-downside having higher than the 3-month average volume. The percentage (%) of the 11-upside were +0.41% (STML) to +8.78% (CLBS) while the 21-downside ranged from -0.42% (MDXG) to -13.46% (BLCM).
Write LESS and let the numbers and facts MEAN more ...
Today’s highs:
Sangamo Therapeutics (SGMO) is up +8.06% or +$0.73 to $9.79 after earnings release with Biogen (BIIB) collaboration dollars;
Hammered in today’s market:
- bluebird bio (BLUE), Global Blood Therapeutics (GBT), Editas Medicine (EDIT), Sage therapeutics (SAGE), CRISPR Therapeutics (CRSP) and ReNeuron (RENE.L), to name a few of the 21
Jumping with momentum:
- Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE), Sangamo Therapeutics (SGMO), BioLife Solutions (BLFS), Intellia Therapeutics (NTLA) to name a few of the 11
Q1/2020 results will be disseminated through RegMed Earnings Scorecard - Q1/20 - to date https://www.regmedinvestors.com/articles/11332 - 25 of 35 so far …
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB closed down -2.13% and XBI also closed down -2.16%
- Monday, the IBB closed up +4.28% and XBI also closed up +4.77%
- Friday, the IBB closed up +0.98% and XBI also closed up +1.46%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was up +5.47 points or +19.84% at 33.04,
- Monday was down -0.41 points or -1.47% at 27.57,
- Friday was down -3.46 points or -11.01% at 27.98,
RegMed/Cell and gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …
- Tuesday opened negative at 5/28 and 2 flats, popped positive at the mid-day at 25/8 and 2 flats and closed negative at 11/21 and 3 flats;
- Monday opened positive at 17/14 and 4 flats, stayed positive at the mid-day at 24/9 and 2 flats and closed positive at 24/9 and 2 flats;
- Friday opened positive at 29/4 and 2 flats, stayed positive at the mid-day at 23/11 and 1 flat and closed positive at 20/12 and 3 flats;
Tuesday’s (top 10) incliners:
- Alnylam Pharmaceuticals (ALNY +$1.76 after Monday’s +$6.30, Friday’s -$5.32, Thursday’s -$3.82, Wednesday’s +$4.04 and last Tuesday’s +$5.27);
- uniQure NV (QURE +$0.86;
- Sangamo Therapeutics (SGMO +$0.73);
- BioLife Solutions (BLFS +$0.34 after Monday’s +$1.28, Friday’s +$0.51 and Thursday’s +$0.58);
- Intellia Therapeutics (NTLA +$0.30 after Monday’s +$1.14 and Monday’s +$1.95);
- Pluristem (PSTI +$0.19 after Monday’s -$0.32, Friday’s +$1.40, Thursday’s -$0.61 and Wednesday’s -$0.28);
- Caladrius Biosciences (CLBS +$0.18);
- Homology Medicine (FIXX +$0.17 after Monday’s +$0.51);
- Solid Biosciences (SLDB +$0.04);
- Aduro Biotech (ADRO +$0.035);
Tuesday (bottom 10) decliners;
- bluebird bio (BLUE -$3.37 after Monday’s -$0.73);
- Global Blood Therapeutics (GBT -$3.14 after Monday’s -$0.20, Friday’s -$0.19, Thursday’s -$4.38, Wednesday’s +$2.50 and last Tuesday’s +$1.62);
- Editas Medicine (EDIT -$1.95 after Monday’s +$2.72, Friday’s +$0.61, Thursday’s -$0.91, Wednesday’s -$0.59 and last Tuesday’s +$0.66);
- Sage Therapeutics (SAGE -$1.84);
- CRISPR Therapeutics (CRSP -$1.74 after Monday’s +$7.45);
- ReNeuron (RENE.L -$1.50 after Monday’s -$7.00, Friday’s +$20.00 and last Thursday’s +$25.00;
- Fate Therapeutics (FATE -$1.47 after Monday’s +$1.38);
- Ultragenyx (RARE -$1.07 after Monday’s +$3.52, Friday’s +$0.72, Thursday’s -$3.14, Wednesday’s +$1.58 and last Tuesday’s -$0.04);
- Adverum Biotechnologies (ADVM -$0.99 after Monday’s -$0.29);
- Regenxbio (RGNX -$0.96 after Monday’s +$2.40 after Friday’s -$1.87);
Percentage (%) movement/range statistics: look closely …
- Tuesday’s % of the 11-upside were +0.41% (STML) to +8.78% (CLBS) while the 21-downside ranged from -0.42% (MDXG) to -13.46% (BLCM);
- Monday’s % of the 24-upside were +0.33% (SAGE) to +15.14% (ATHX) while the 9-downside ranged from -0.12% (STML) to -4.22% (RENE.L);
- Friday’s % of the 20-upside were +0.65% (CRSP) to +31.9% (BLCM) while the 12-downside ranged from -0.07% (NTLA) to -4.58% (RGNX);
Sentiment and a few daily indicators:
Stocks poised to benefit from economies reopening — retail and real estate— rolled over in afternoon trading, dragging down the major averages. Investors also cooled off allowing the Nasdaq to slip red, nip green and flip red and back-end again into the red.
The number of confirmed U.S. coronavirus cases: every day I get sadder as I post these numbers …
- Tuesday 1.3 million,
- Monday 1.3 million,
- Friday 1.2 million,
Tuesday’s death rate escalated to a total of 80,897 after Monday’s 79,894 after Friday’s 75,852 <John Hopkins University>
Upside volume stats:
- Tuesday: 8 out of the 11-upside had higher than the 3-month average volume;
- Monday: 12 out of the 24-upside had higher than the 3-month average volume;
- Friday: 8 out of the 20-upside had higher than the 3-month average volume;
Downside volume stats:
- Tuesday: 9 out of the 21-downside had higher than the 3-month average volume;
- Monday: 2 out of the 9-downside had higher than the 3-month average volume;
- Friday: 3 out of the 12-downside had higher than the 3-month average volume;
Closing flat: Brainstorm cell therapeutics (BCLI), Biostage (BSTG) and Mesoblast (MESO)
May
Tuesday closed negative with 21 decliners, 11 advancer and 3 flats
Friday (5/8) closed positive with 12 decliners, 20 advancer and 3 flats
Thursday closed negative with 22 decliners, 11 advancer and 2 flats
Wednesday closed positive with 13 decliners, 20 advancer and 2 flats
Tuesday closed positive with 10 decliners, 25 advancer and 0 flats
Monday (5/4) closed positive with 7 decliners, 28 advancer and 0 flats
Friday (5/1) closed negative with 25 decliners, 8 advancer and 2 flats
The BOTTOM LINE: As I said, I’d rather safe than sorry as “prior planning prevents poor performance” - so always be prepared for the worst in this pandemic period.
And I was RIGHT, growth was bullet prove in early 2020 … now with social distancing, a face cover and a Kevlar reinforced jacket is needed as protection from “sticks and stones breaking the bones” from markets as the sector responds to higher momentum.
- The rhyme is used as a defense against name-calling and verbal bullying which is intended to increase resiliency, avoid physical retaliation and to remain calm and good-living.
Back to my mantra, SELL the highs, BUY the lows and do it again and then again!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
